PLUS
Plasma-Lyte 148 versus Saline
Paziente / Popolazione Intervento / Esposizione Confronto Esito
In 5,037 ICU patients, Plasma-Lyte 148 did not change 90-day mortality versus saline.
N
5037
Disegno
Multicentre RCT, ANZ
Esito
90-day all-cause mortality
Rilevanza
3
Risultato21.8% vs 22.0%; AKI similar.
Finfer S, et al. N Engl J Med. 2022;386(9):815-826. 10.1056/NEJMoa2114464
Discussione e critica
Largest single trial of balanced vs saline; consistent with small benefit from meta-analysis.